Kyle T. Baron, Pharm.D., Ph.D.

Group Leader PKPD, Principal Scientist II

Kyle joined MetrumRG in 2010 after receiving his Pharm.D. and Ph.D. in  Experimental and Clinical Pharmacology from the University of Minnesota. As a member of our translational and systems pharmacology group, Kyle has worked to support sponsor development programs in a variety of therapeutic areas, including chronic hepatitis C infection, HIV, calcium homeostasis and bone health, type-2 diabetes, and cystic fibrosis.  

Kyle is the developer and maintainer of mrgsolve ( and also leads workshops at all levels to guide other M&S scientists in the effective use of this simulation tool in PKPD, PBPK, and QSP modeling. Kyle also serves as adjunct faculty in Experimental and Clinical Pharmacology at the University of Minnesota.  

Recent publications by this scientist

simpar: an R Package for Parameter Uncertainty Simulations in Pharmacometric Modeling

November 15, 2023

Presented at ACoP14. This project is dedicated to integrating parameter uncertainty into pharmacometric simulations, which plays a crucial role in making informed decisions in drug development. Initially, the metrumrg package in R was instrumental for simulating both fixed and random effect parameters. However, this package has since been deprecated. Consequently, the primary objective was to create a new R package named simpar. This new package aimed to retain the essential functionalities of metrumrg while expanding its capabilities. The overarching goal was to significantly enhance the support for incorporating parameter uncertainty into pharmacometric simulations, thereby aiding more comprehensive and accurate decision-making processes in this field.

Download PDF

Population Pharmacokinetic and Exposure-Response Analysis of Linagliptin in Pediatric Patients with Type 2 Diabetes Mellitus

November 15, 2023

Presented at ACoP14. This study assessed linagliptin’s effectiveness and safety in children and adolescents with type 2 diabetes over 26 weeks, potentially extending to 52 weeks. The study re-evaluated models developed for adults and adolescents to understand linagliptin’s impact on pediatric patients’ HbA1c levels. Results indicated slightly higher and more varied linagliptin exposure in children compared to adults at a 5 mg dose. Although pediatric patients had a smaller and variable HbA1c reduction versus adults at week 26, the Bayesian approach helped characterize linagliptin’s effects in children based on limited data, borrowing insights from adult studies.

Download PDF

Landmark and longitudinal exposure-response analyses for multiple efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma

December 15, 2022

Masato Fukae, Kyle Baron, James Rogers, Ramon Garcia, Masaya Tachibana, John Mondick, Takako Shimizu. Poster presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October – November 2 2022. Poster M-026

Download PDF